CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

CD19-targeted therapy Breyanzi (lisocabtagene maraleucel) can now be used to treat adults with MZL – a rare and form of ...

Bristol Myers (BMY) “announced that the FDA has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a ...

The CAR T Vision Steering Committee has set an ambitious goal: to double the proportion of eligible patients treated with CAR T by 2030. 2 Reimbursement challenges stand out as an area where ...

Bristol Myers Squibb BMY recently obtained FDA approval for the label expansion of Breyanzi (lisocabtagene maraleucel) for ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow. CAR-T cell therapy has cured some children ...

CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...

The U.S. Food and Drug Administration has approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first ...

(Yicai) Dec. 5 -- China is becoming a global center for chimeric antigen receptor-T cell therapy, which re-engineers a ...